- Vaping Linked to Earlier Onset of Asthma
- FDA Approves New Drug for Deadly Lung Cancer
- U.S. Justice Department Moves to Reclassify Weed as Less Risky Drug
- Global Life Expectancy Could Rise By More Than 4 Years by 2050
- Most Cancer Treatments Near End of Life Are Useless: Study
- Brain’s ‘Food Smell’ Circuitry Might Drive Overeating
- The More Kids Use Social Media, The More They’re Likely to Vape
- Men Are More Debilitated by Diabetes Than Women
- Is Your Child Ready for Summer Sleepaway Camp?
- Leptospirosis: What Every Dog Owner Should Know
Cresemba Approved for Serious Fungal Infections
Cresemba (isavuconazonium sulfate) has been approved by the U.S. Food and Drug Administration to treat rare but serious fungal infections, mostly affecting people with weakened immune systems, the agency said Friday in a news release.
The infections are caused by Aspergillus and Mucorales fungi. The new drug, targeting the cell walls of the fungi, is available in oral and intravenous formulations.
Cresmba’s safety and effectiveness were evaluated in clinical studies involving more than 500 people. The most common side effects included nausea, vomiting, diarrhea, headache, low blood potassium, constipation, shortness of breath, coughing and tissue swelling. More serious adverse effects could include liver problems and allergic reactions.
Cresemba is marketed by Astellas Pharma US, based in Northbrook, Ill.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.